Our StrategyVision-Driven Innovationin Drug & Cell Delivery
At Likarda, we’re reshaping the future of therapeutics by solving some of the most complex delivery and formulation challenges in healthcare. Our patented Core-Shell Spherification® (CSS®) platform enables long-acting injectables, immune-shielded delivery, and enhanced therapeutic viability—all while maintaining full biocompatibility and safety.
A Platform-First Commercialization Model
As a pure-play delivery platform company, Likarda partners exclusively with biopharma, biotech, and CDMOs to bring next-generation therapies to life. We do not develop our own therapeutics—ensuring we remain laser-focused and fully aligned with our partners’ success across a wide spectrum of modalities.
Strategic Validation in Three High-Impact Categories:
Biologics & Peptides
We enable sustained-release formulations for fragile proteins, hormones, and peptides—reducing dosing frequency, improving patient compliance, and extending therapeutic duration.
Cell & Gene Therapies
Our platform is designed to protect cell therapies during delivery, storage, and transport, with approaches that may extend viable storage windows and simplify cold-chain requirements.
Regenerative Medicine
CSS® technology creates optimized microenvironments for stem cells, iPSCs, MSCs, and extracellular vesicles, enhancing retention, functionality, and survival following in vivo delivery.
Built to Scale. Built to Partner.
Each engagement is structured to:
- Expand our growing intellectual property portfolio
- Design formulations and processes with downstream regulatory requirements in mind
- Extend product lifecycles through differentiated delivery
We operate behind the scenes—and measure our success by the impact and adoption of our partners’ therapies.
Strategic Partnerships & Licensing
Our partnership-first model is designed to scale impact across the ecosystem. We collaborate with:
- Biopharma innovators seeking differentiated delivery systems
- CDMOs and platform integrators for clinical and commercial manufacturing
- Academic and clinical researchers exploring new therapeutic frontiers
Through these collaborations, we accelerate co-development, drive market adoption, and unlock the full commercial potential of our CSS® platform.
Our Partners
Scalable Manufacturing
With a closed-loop, modular manufacturing system launching in 2027, we are enabling:
- GMP-compliant encapsulation at clinical and commercial scale
- Standardized process validation for regulatory alignment
- Custom formulations with consistent bead size, purity, and release kinetics
Supporting Regulatory-Ready Development
CSS® formulations can incorporate biocompatible materials with established histories of use in pharmaceutical and biomedical applications. Combined with controlled manufacturing processes and early preclinical evaluation, this provides a strong foundation for product-specific development and regulatory planning.
CSS® is designed to encapsulate therapeutic payloads without chemically modifying the active ingredient. Depending on the product, indication, and route of administration, this approach may offer development advantages while supporting regulatory strategies appropriate to the specific program, including potential 505(b)(2) or BLA pathways.
Partner with Likarda
Unlock new possibilities for injectable therapies. Whether you’re developing a fragile biologic, advancing a cell therapy, pursuing sustained or localized delivery, or addressing storage and stability challenges, our team can help determine whether CSS® is the right fit for your program.
Let’s discuss your development challenge.